FDA approves Uptravi IV for pulmonary arterial hypertension – J&J
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension… read more.